Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 19;12(1):1685350. doi: 10.1080/19420862.2019.1685350

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Bristol Myers Squibb. Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 6. — CD3/CD20 bispecific antibodies deplete B-cells in vivo. Wild-type C57BL/6 mice were treated with a single 1 mg/kg dose of CD3/CD20 or CD3/Neg in both mG1_KD D265A and mG2a_H4 D265A. (a) After 7 days, CD19 + B-cells were measured by flow cytometry (mean ± SD, n = 4). (b) In a second study, wild-type C57BL/6 were treated with a single 1 mg/kg dose of CD3/CD20 mG2a_H4 D265A, CD3/Neg mG2a_H4 D265A, or CD20 mG2a. Circulating B-cells were measured by flow cytometry at 0, 1, 2, 3, 4, and 7 days (mean ± SD, n = 4). (c) Spleens were harvested at day 7 and B-cells measured by flow cytometry (mean ± SD, n = 4). (d) Pharmacokinetic (PK) data were collected from wild-type C57BL/6 treated with 1 mg/kg CD3/CD20 or CD3/Neg in both mG1_KD D265A, mG2a_H4, and mG2a_H4 D265A backbones. Serum concentrations were measured at 0, 1, 7, 14, and 21 days.